INHALERX ORD
Weekly wrap: RBA was right on rates and it cost us a record
There will be no letup in the political attacks against it but the share market has finally conceded that the Reserve Bank was absolutely right not to cut interest rates this year. With Australian employment growth now hitting a 16-month high and workforce participation at a record, with inflation still sticky, the Reserve Bank’s caution […]
InhaleRx procures $38.5m in funding from Clendon Biotech to progress inhaled therapies
Healthcare company InhaleRx (ASX: IRX) has entered into an agreement with Melbourne-headquartered Clendon Biotech Capital to provide up to $38.5 million in funding to cover costs associated with developing it’s unique inhaled therapies. Clendon’s funding will fully cover the costs – including those from associated non-clinical work and trial drug manufacturing – for the IRX-211 […]
InhaleRx submits ethics application for IRX616a to treat panic disorder
Australian healthcare company InhaleRx (ASX: IRX) has submitted an ethics application for a Phase 2a clinical trial investigating the safety and efficacy of lead candidate IRX616a in patients with panic disorder. The application was submitted to Bellberry Human Research Ethics Committee last week and is based on a proof-of-concept trial to be carried out at […]
InhaleRx completes second cohort of IRX211 trial for pain management
Australian healthcare company InhaleRx (ASX: IRX) has completed the second of four cohorts in a Phase 1 clinical trial investigating the safety and pharmacokinetics of lead cannabinoid drug delivery system IRX211. The company has now recruited and dosed 16 participants across the first and second cohorts of the trial, which is focused on potential treatments […]